HAIFA, Israel, September 26 /PRNewswire/ -- InSightec's ExAblate(R) 2000,
the first U.S. Food and Drug Administration (FDA) approved Magnetic
Resonance-guided Focused Ultrasound (MRgFUS) technology for the non-invasive
treatment of uterine fibroids has once again been recognized for technology
achievement, the company said today. Frost & Sullivan, the international
growth consultant, has awarded InSightec its 2005 Technical Innovation Award
in the field of non-invasive medical devices for outstanding industry
Frost & Sullivan's gives the Technology Innovation award to a company
that has carried out new research that has resulted in innovation expected to
bring significant contributions to its industry in terms of adoption, change,
and competitive posture. This award recognizes the quality and depth of a
company's research and development program as well as the vision a company
had and the risks it took to undertake such an endeavor.
"This is the fourth in a line of prestigious awards InSightec has
received for the ExAblate 2000 technology," Dr. Jacob Vortman, president and
CEO, InSightec said. "We are pleased by this, but more importantly, we are
rewarded that so many women have already benefited from this patient-friendly
solution for treating uterine fibroids and are investing in research on
future applications that will enable other patients suffering from breast
cancer, liver cancer, bone tumors, prostate cancer and brain tumors to be
treated non-invasively for their tumors."
In November 2004, The Wall Street Journal awarded the Company a Bronze
Medal and Second Place in the Medical Category as part of its annual
Technology Innovation Awards. Out of 585 applicants, the Journal picked the
novel ideas that best addressed big challenges and had a wide-reaching
impact. Rigorous data had to support the winners' real-world performance.
Also in 2004, the European Information Society Technology awarded
InSightec the IST Grand Prize, the most distinguished European Prize for
innovative products and services in the field of information society
technology. The award is given based on technical excellence, innovative
content, potential market value, and the capacity to generate new jobs. Most
recently, the ExAblate 2000 was also recognized by Advanced Imaging in its
2005 Solutions of the Year issue.
The ExAblate 2000 uses magnetic resonance imaging (MRI) in conjunction
with highly-focused ultrasound to thermally ablate (destroy) tumors in the
body. The unique MR thermometry feedback, provided by the system, allows the
physician to monitor and control the treatment to ensure that the targeted
tumor is fully treated and the healthy tissue is avoided. The ExAblate 2000
is compatible only with GE Healthcare's SIGNA Magnetic Resonance systems.
The system is currently in use at centers around the world for the
treatment of uterine fibroids and clinical research trials are underway for
potential applications in the treatment of both benign and cancerous tumors.
For more information about the ExAblate(R) 2000 or InSightec, please
InSightec Image Guided Treatment Ltd. is a privately held company owned
by Elbit Medical Imaging (EMI), General Electric, private investors and
employees. It was founded in 1999 to develop the breakthrough MR guided
Focused Ultrasound technology and transform it into the next generation
operating room. Headquartered near Haifa, Israel, the company has over 100
employees and has invested more than $80 million in research, development,
and clinical investigations. Its U.S. headquarters are located in Dallas,
Texas. For more information, please go to: http://www.insightec.com/
For media inquiries, contact:
Lazar Partners, Ltd.
For more information, please visit http://www.uterine-fibroids.org
SOURCE Insightec Ltd.